Analysts think QNCX stock price could increase by 7135%
Jun 14, 2024, 6:28 AM
1.25%
What does QNCX do
Quince Therapeutics, a biopharmaceutical company based in South San Francisco, develops drugs for rare diseases and went public in 2019. They focus on EryDex for Ataxia-Telangiectasia treatment, utilizing their AIDE technology for optimized drug delivery.
4 analysts think QNCX stock price will increase by 7134.56%. The current median analyst target is $50.49 compared to a current stock price of $0.70. The lowest analysts target is $3.03 and the highest analyst target is $100.80.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.